Value Sense
SLN
Silence Therapeutics plc (SLN)
Last Price$4.3(4.0%)
Market Cap$211.4B
LTM P/E
(2,826.5x)
EPS growth
(38.4%)
PEGY
73.7x
Peter Lynch Fair Value
$0.1
Overvalued (Peter Lynch formula)
(98.6%)
Stock quality
6/10
Good
SLN
is 99.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

SLN Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 10, 2025
LTM P/E
(2,826.5x)
EPS growth
(38.4%)
Dividend Yield
0.0%
PEGY
73.7x
Last share price
$4.3
Peter Lynch Fair Value
$0.1
98.6% overvalued

Peter Lynch Fair Value Calculation

PEGY
73.7x
=
LTM P/E
(2,826.5x)
/
(
EPS growth
(38.35%)
+
Dividend yield
0.00%
)
Peter Lynch
Fair Value
$0.1
=
Last share price
$4.3
/
PEGY
73.7x

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

SLN EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

SLN vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Silence Therapeutics plc logo
Silence Therapeutics plcSLN
(98.6%)
45.7%
(6.7%)
(170.5%)
Median Peer Set
23.0%
(56.5%)
0.8%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
3,245.7%
73.7%
(56.5%)
(35.9%)
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
(45.9%)
8.3%
10.4%
31.1%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
(50.9%)
23.6%
25.7%
41.5%
Incyte Corporation logo
Incyte CorporationINCY
27.3%
14.8%
(94.0%)
0.8%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
(18.5%)
24.9%
142.8%
34.8%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(137.6%)
N/A
(68.7%)
N/A
BioNTech SE logo
BioNTech SEBNTX
N/A
(77.4%)
(89.7%)
24.4%
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
N/A
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
N/A
11.7%
N/A
(4.9%)

Explore more intrinsic value tools hub for SLN

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Silence Therapeutics plc fair value by Peter Lynch formula?

As of Mar 03, 2025, Silence Therapeutics plc's fair value using the Peter Lynch formula is $0.1 per share. The current price of $4.3 suggests Silence Therapeutics plc may be overvalued by this metric.

What is Silence Therapeutics plc Price to Earnings (P/E) ratio?

As of Mar 03, 2025, Silence Therapeutics plc's P/E ratio is (2,826.5x). This is calculated by dividing the current share price of $4.3 by the Earnings per Share (EPS) for the trailing twelve months, which is ($0.7). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Silence Therapeutics plc earnings per share (EPS)?

Silence Therapeutics plc earnings per share (EPS) for the twelve months ending Mar 03, 2025, was ($0.7), a (38.4%) growth year-over-year.